PROTACs

SMALL MOLECULES

RESULTS SO FAR

UNPRECEDENTED EFFECTS ON BIOAVAILABILITY

PIPELINE FOCUS

The results depicted in the pipeline table above are unprecedented re bioavailibility.

We have identified many more parenteral compounds that we can turn into an oral variant. We mainly focus on the following compounds right now, hereby creating true added value to the patients and society:

  • Ceftriaxon
  • Fulvestrant
  • Meropenem

FURTHER OPPORTUNITIES

In addition to the above compounds, we have applied NDCt to many other compounds, but have not been able to test all of them so far, among them:

Click on the tabs below to see the compounds per category.

AND MANY MORE OPPORTUNITIES

There are many compounds in various disease areas where patients could benefit from NDCt.

We work with a shortlist of 60 compounds – and this list is currently growing. Be inspired by our list of compounds and let us ‘solve’ your problems.

Click on the tabs below to see the compounds per category.

PHARMACYTICS EXPLORES PEPTIDES